UniProt P37231
Peroxisome proliferator-activated receptor gamma (P37231)
Peroxisome proliferator-activated receptor gamma (UniProt P37231): 446 experimental structures on GenesisL1, 83 ligands bound, 157 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- P37231
- Protein
- Peroxisome proliferator-activated receptor gamma
- Experimental structures
- 446
- Predicted models
- 0
- Ligands
- 83
- Pockets
- 157 · 31 records with a druggable one
Structures
446 records of P37231 in the MolNFT archive: 446 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1FM6 | The 2.1 ångström resolution crystal structure of the heterodimer of the human rxralpha and… | x-ray diffraction | D, X | — | — |
| 1FM6 | The 2.1 ångström resolution crystal structure of the heterodimer of the human rxralpha and… | x-ray diffraction | D, X | — | — |
| 1FM9 | The 2.1 ångström resolution crystal structure of the heterodimer of the human rxralpha and… | x-ray diffraction | D | — | — |
| 1FM9 | The 2.1 ångström resolution crystal structure of the heterodimer of the human rxralpha and… | x-ray diffraction | D | — | — |
| 1I7I | Crystal structure of the ligand binding domain of human ppar-gamma in complex with the agonist az… | x-ray diffraction | A, B | — | — |
| 1I7I | Crystal structure of the ligand binding domain of human ppar-gamma in complex with the agonist az… | x-ray diffraction | A, B | — | — |
| 1K74 | The 2.3 Angstrom resolution crystal structure of the heterodimer of the human PPARgamma and… | x-ray diffraction | D | — | — |
| 1K74 | The 2.3 ångström resolution crystal structure of the heterodimer of the human ppargamma and… | x-ray diffraction | D | — | — |
| 1KNU | Ligand binding domain of the human peroxisome proliferator activated receptor gamma in complex with… | x-ray diffraction | A, B | — | — |
| 1KNU | Ligand binding domain of the human peroxisome proliferator activated receptor gamma in complex with… | x-ray diffraction | A, B | — | — |
| 1NYX | Ligand binding domain of the human peroxisome proliferator activated receptor gamma in complex with… | x-ray diffraction | A, B | — | — |
| 1NYX | Ligand binding domain of the human peroxisome proliferator activated receptor gamma in complex with… | x-ray diffraction | A, B | — | — |
| 1PRG | Ligand binding domain of the human peroxisome proliferator activated receptor gamma | x-ray diffraction | A, B | — | — |
| 1PRG | Ligand binding domain of the human peroxisome proliferator activated receptor gamma | x-ray diffraction | A, B | — | — |
| 1RDT | Crystal Structure of a new rexinoid bound to the RXRalpha ligand binding doamin in the… | x-ray diffraction | D | — | — |
| 1RDT | Crystal structure of a new rexinoid bound to the rxralpha ligand binding doamin in the… | x-ray diffraction | D | — | — |
| 1ZEO | Crystal Structure of Human PPAR-gamma Ligand Binding Domain Complexed with an… | x-ray diffraction | A, B | — | — |
| 1ZEO | Crystal structure of human ppar-gamma ligand binding domain complexed with an… | x-ray diffraction | A, B | — | — |
| 1ZGY | Structural and Biochemical Basis for Selective Repression of the Orphan Nuclear Receptor LRH-1 by… | x-ray diffraction | A | — | — |
| 1ZGY | Structural and biochemical basis for selective repression of the orphan nuclear receptor lrh-1 by… | x-ray diffraction | A | — | — |
| 2ATH | Crystal structure of the ligand binding domain of human PPAR-gamma im complex with an agonist | x-ray diffraction | A, B | — | — |
| 2ATH | Crystal structure of the ligand binding domain of human ppar-gamma im complex with an agonist | x-ray diffraction | A, B | — | — |
| 2F4B | Crystal structure of the ligand binding domain of human PPAR-gamma in complex with an agonist | x-ray diffraction | A, B | — | — |
| 2F4B | Crystal structure of the ligand binding domain of human ppar-gamma in complex with an agonist | x-ray diffraction | A, B | — | — |
| 2FVJ | A novel anti-adipogenic partial agonist of peroxisome proliferator-activated receptor-gamma (PPARG)… | x-ray diffraction | A | — | — |
| 2FVJ | A novel anti-adipogenic partial agonist of peroxisome proliferator- activated receptor-gamma… | x-ray diffraction | A | — | — |
| 2G0G | Structure-based drug design of a novel family of PPAR partial agonists: virtual screening, x-ray… | x-ray diffraction | A, B | — | — |
| 2G0G | Structure-based drug design of a novel family of ppar partial agonists: virtual screening, X-ray… | x-ray diffraction | A, B | — | — |
| 2GTK | Structure-based Design of Indole Propionic Acids as Novel PPARag CO-Agonists | x-ray diffraction | A | — | — |
| 2GTK | Structure-based design of indole propionic acids as novel pparag co- agonists | x-ray diffraction | A | — | — |
| 2HWQ | Structural basis for the structure-activity relationships of Peroxisome Proliferator-Activated… | x-ray diffraction | A, B | — | — |
| 2HWQ | Structural basis for the structure-activity relationships of peroxisome proliferator-activated… | x-ray diffraction | A, B | — | — |
| 2HWR | Structural basis for the structure-activity relationships of Peroxisome Proliferator-Activated… | x-ray diffraction | A, B | — | — |
| 2HWR | Structural basis for the structure-activity relationships of peroxisome proliferator-activated… | x-ray diffraction | A, B | — | — |
| 2I4J | Crystal structure of the complex between PPARgamma and the agonist LT160 (ureidofibrate derivative) | x-ray diffraction | A, B | — | — |
| 2I4J | Crystal structure of the complex between ppargamma and the agonist LT160 (ureidofibrate derivative) | x-ray diffraction | A, B | — | — |
| 2I4P | Crystal structure of the complex between PPARgamma and the partial agonist LT127 (ureidofibrate… | x-ray diffraction | A, B | — | — |
| 2I4P | Crystal structure of the complex between ppargamma and the partial agonist LT127 (ureidofibrate… | x-ray diffraction | A, B | — | — |
| 2I4Z | Crystal structure of the complex between PPARgamma and the partial agonist LT127 (ureidofibrate… | x-ray diffraction | A, B | — | — |
| 2I4Z | Crystal structure of the complex between ppargamma and the partial agonist LT127 (ureidofibrate… | x-ray diffraction | A, B | — | — |
| 2OM9 | Ajulemic acid, a synthetic cannabinoid bound to PPAR gamma | x-ray diffraction | A, B, C, D | — | — |
| 2OM9 | Ajulemic acid, a synthetic cannabinoid bound to ppar gamma | x-ray diffraction | A, B, C, D | — | — |
| 2P4Y | Crystal structure of human PPAR-gamma-ligand binding domain complexed with an indole-based modulator | x-ray diffraction | A, B | — | — |
| 2P4Y | Crystal structure of human ppar-gamma-ligand binding domain complexed with an indole-based modulator | x-ray diffraction | A, B | — | — |
| 2POB | PPARgamma Ligand binding domain complexed with a farglitazar analogue gw4709 | x-ray diffraction | A, B | — | — |
| 2POB | Ppargamma ligand binding domain complexed with a farglitazar analogue GW4709 | x-ray diffraction | A, B | — | — |
| 2PRG | Ligand-binding domain of the human peroxisome proliferator activated receptor gamma | x-ray diffraction | A, B | — | — |
| 2PRG | Ligand-binding domain of the human peroxisome proliferator activated receptor gamma | x-ray diffraction | A, B | — | — |
| 2Q59 | Crystal Structure of PPARgamma LBD bound to full agonist MRL20 | x-ray diffraction | A, B | — | — |
| 2Q59 | Crystal structure of ppargamma lbd bound to full agonist MRL20 | x-ray diffraction | A, B | — | — |
| 2Q5P | Crystal Structure of PPARgamma bound to partial agonist MRL24 | x-ray diffraction | A, B | — | — |
| 2Q5P | Crystal structure of ppargamma bound to partial agonist MRL24 | x-ray diffraction | A, B | — | — |
| 2Q5S | Crystal Structure of PPARgamma bound to partial agonist nTZDpa | x-ray diffraction | A, B | — | — |
| 2Q5S | Crystal structure of ppargamma bound to partial agonist ntzdpa | x-ray diffraction | A, B | — | — |
| 2Q61 | Crystal Structure of PPARgamma ligand binding domain bound to partial agonist SR145 | x-ray diffraction | A, B | — | — |
| 2Q61 | Crystal structure of ppargamma ligand binding domain bound to partial agonist SR145 | x-ray diffraction | A, B | — | — |
| 2Q6R | Crystal structure of PPAR gamma complexed with partial agonist SF147 | x-ray diffraction | A, B | — | — |
| 2Q6R | Crystal structure of ppar gamma complexed with partial agonist SF147 | x-ray diffraction | A, B | — | — |
| 2Q6S | 2.4 angstrom crystal structure of PPAR gamma complexed to BVT.13 without co-activator peptides | x-ray diffraction | A, B | — | — |
| 2Q6S | 2.4 ångström crystal structure of ppar gamma complexed to BVT.13 without co-activator peptides | x-ray diffraction | A, B | — | — |
386 records more on the page itself.
Ligands
- EDK · (2~{S})-3-[4-[2-[methyl(pyridin-2-yl) amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl) phenyl]amino]propanoic acid · in 17 records
- KNA · nonanoic acid · in 8 records
- CL · Chloride ion · in 7 records
- GW9 · 2-chloro-5-nitro-N-phenylbenzamide · in 6 records
- BRL · 2,4-thiazolidiinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-(9CL) · in 5 records
- SO4 · Sulfate ion · in 5 records
- EEY · 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide · in 4 records
- MLQ · (2~{R})-2-[[6-[(2,4-dichlorophenyl)sulfonylamino]-1,3-benzothiazol-2-yl]sulfanyl]octanoic acid · in 4 records
- OLA · Oleic acid · in 4 records
- 8LX · (5S)-5-[[4-[2-[[6-(4-methoxyphenoxy)pyrimidin-4-yl]-methyl-amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2, 4-dione · in 3 records
- ACD · Arachidonic acid · in 3 records
- 5IV · ~{N}-[[4-(cyclopropylsulfonylamino)-2-(trifluoromethyl)phenyl]methyl]-1-[(3-fluorophenyl) methyl]indole-5-carboxamide · in 2 records
- 8N6 · (5S)-5-[[4-[2-(5-ethylpyridin-2-yl) ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione · in 2 records
- 8Y0 · (E)-N-[(3E)-2-oxo-16-(8-{6-[(trifluoroacetyl) amino]hexanoyl}-8,9-dihydro-1H-dibenzo[b,f][1,2, 3]triazolo[4,5-d]azocin-1-yl)hexadec-3-en-1-ylidene]glycine · in 2 records
- A0L · 2-butyl-5-[(3-tert-butyl-1,2,4-oxadiazol-5-yl)methyl]-6-methyl-3-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl}pyrimidin-4(3H)-one · in 2 records
- B0X · 3-[[6-(2,6-dimethylpyridin-3-yl)oxy-1-methyl-benzimidazol-2-yl]methoxy]benzoic acid · in 2 records
- B1O · 3-[[6-(2,6-dimethylpyridin-3-yl)oxy-7-fluoranyl-1-methyl-benzimidazol-2-yl]methoxy]benzoic acid · in 2 records
- BKY · 4-({2-[(1,3-dioxo-1,3-dihydro-2H-inden-2-ylidene) methyl]phenoxy}methyl)benzoic acid · in 2 records
- CTU · 3-[(1~{E})-1-[8-[(8-chloranyl-2-cyclopropyl-imidazo[1, 2-a]pyridin-3-yl)methyl]-3-fluoranyl-6~{H}-benzo[c][1]benzoxepin-11-ylidene]ethyl]-4~{H}-1,2,4-oxadiazol-5-one · in 2 records
- EB6 · Methyl (2~{S})-3-[4-[3-(4-methoxy-2-oxidanyl-phenyl) prop-2-ynoyloxy]phenyl]-2-[[2-(phenylcarbonyl) phenyl]amino]propanoate · in 2 records
- EBF · 7-methoxychromen-2-one · in 2 records
- GEV · (5Z)-5-({4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl) propanoyl]phenyl}methylidene)-1,3-thiazolidine-2,4-dione · in 2 records
- GH1 · (5S)-5-({4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione · in 2 records
- IOD · Iodide ion · in 2 records
- KK4 · 3-[(1E)-1-{8-[(4-methyl-2-propyl-1H-benzimidazol-1-yl) methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}ethyl]-1,2,4-oxadiazol-5(4H)-one · in 2 records
- NA · Sodium ion · in 2 records
- NZA · 5-chloro-1-(4-chlorobenzyl)-3-(phenylthio)-1H-indole-2-carboxylic acid · in 2 records
- QZQ · Betulinic Acid · in 2 records
- RTE · 3-{[6-(4-chloro-3-fluorophenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy}benzoic acid · in 2 records
- STI · 4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide · in 2 records
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.